- Market Realist•5 hours ago
On July 28, 2016, Pfizer announced positive results from the Phase 3 trial testing efficacy of Xeljanz as therapy for patients suffering with moderate to severely active ulcerative colitis (or UC).
- Market Realist•6 hours ago
Wall Street analysts estimate that Enbrel’s sales in 2016 will reach approximately $3.0 billion, which would be a year-over-year (or YoY) decline of ~9.1%.
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||32.40 x 36500|
|Ask||32.41 x 52900|
|Day's Range||32.15 - 32.60|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.72|
|Avg Vol (3m)||19,076,441|
|Dividend & Yield||1.20 (3.73%)|